Table 2.

Data set of included patient characteristics.

Patient number	Follow-up time	Re-recurrence eventa	Death eventb	BMI	Differentation gradec	Myometrial invasiond	FIGO stagee	Tumor sizef	Ageg	Histological typeh
Radiotherapy treatment
1	10.31	6.19	8.94	21.23	1	−	1A	+	72	ED
2	9.35	3.11	7.23	27.51	2	−	1A	−	80	ED
3	8.41	–	–	n/a	2	+	1B	−	58	ED
4	7.76	0.88	2.79	27.14	2	+	1B	−	79	ED
5	7.59	–	2.24	23.96	3	+	1B	−	82	ED
6	11.09	2.97	3.08	n/a	1	−	1A	−	78	ED
7	3.59	–	–	28.53	1	+	1B	−	78	ED
8	4.51	–	–	22.66	2	+	1B	−	77	ED
9	6.23	0.79	0.89	n/a	2	+	1B	+	61	ED
10	7.7	2.11	7.11	27.95	1	−	1A	+	78	ED
11	2.39	–	–	18.99	3	+	1B	+	68	ED
12	1.53	–	–	23.62	2	+	1B	−	69	ED
13	4.06	0a	3.16	26.44	2	+	3C	−	67	ED
14	1.93	–	–	57.16	1	−	1A	+	58	ED
15	3.99	1.69	2.56	22.41	3	+	1B	−	69	CS
16	2.46	–	–	25.31	1	−	1A	−	62	ED
17	4.14	–	–	34.19	2	−	1A	+	60	ED
18	2.4	–	–	22.32	3	+	1B	−	60	ED
19	2.02	–	–	27.47	1	+	2	+	63	ED
20	2.31	–	–	36.73	3	+	3A	+	81	ED
21	2.41	–	–	n/a	2	−	1A	−	52	ED
22	1.62	0.79	1.62	25.64	1	−	2	−	73	ED
23	1.39	–	–	31.86	2	−	1A	−	63	ED
24	2.07	0.91	1.89	35.16	3	−	1A	+	72	CC
25	1.57	0.08	–	16	1	−	1A	−	79	ED
26	2.22	0i	1.11	n/a	3	−	1A	−	68	SA
Combined treatment
1	3.93	–	–	n/a	2	+	1C	+	60	ED
2	6.78	3.93	–	n/a	3	+	3A	+	59	ED
Surgical treatment
1	4.61	–	–	22.22	2	+	1B	−	62	ED
2	4.16	–	–	n/a	3	+	3C	−	84	CS
3	4.89	–	–	22.77	2	−	1A	+	80	ED
4	3.25	2.29	–	22.23	2	+	1B	+	72	ED
5	2.47	–	–	n/a	2	−	1A	−	80	ED

^aRe-recurrence in years after recurrence.

^bDeath in years after recurrence, surviving patients as –.

^cDifferentiation grade is histological differentiation of endometrioid adenocarcinoma grade 1 as high differentiation to grade 3 low differentiation.

^dAt + invasion is through 50% of the wall, − less than.

^eFIGO stage follows the 2009 revision

^fTumor size above 2 cm as +. Below 2 cm as −.

^gAge at the time of primary cancer diagnosis.

^hED = endometrioid adenocarcinoma. CS = carcinosarcoma. CC = clear cell carcinoma. SA = serous adenocarcinoma.

ⁱWere never cured of their recurrence.